Tim Ward

4.8k total citations · 2 hit papers
40 papers, 3.5k citations indexed

About

Tim Ward is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tim Ward has authored 40 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 18 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tim Ward's work include Cancer Cells and Metastasis (8 papers), Cancer Genomics and Diagnostics (8 papers) and Cancer therapeutics and mechanisms (7 papers). Tim Ward is often cited by papers focused on Cancer Cells and Metastasis (8 papers), Cancer Genomics and Diagnostics (8 papers) and Cancer therapeutics and mechanisms (7 papers). Tim Ward collaborates with scholars based in United Kingdom, United States and France. Tim Ward's co-authors include Caroline Dive, Fiona Blackhall, Matthew Krebs, Robert Szczepaniak‐Sloane, Lynsey Priest, Malcolm Ranson, Lee Lancashire, Andrew Hughes, Alastair Greystoke and Glen Clack and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Tim Ward

39 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer

2011 709 citations Matthew Krebs, Robert Szczepaniak‐Sloane et al. Journal of Clinical Oncology profile →
Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer

2012 675 citations Matthew Krebs, Lee Lancashire et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tim Ward United Kingdom	26	2.4k	1.5k	1.0k	1000	573	40	3.5k
Lynsey Priest United Kingdom	15	2.2k 0.9×	1.6k 1.1×	889 0.9×	854 0.9×	520 0.9×	22	3.1k
Alastair Greystoke United Kingdom	28	2.3k 1.0×	1.4k 0.9×	1.3k 1.3×	1.3k 1.3×	349 0.6×	144	3.8k
Sofia Agelaki Greece	40	3.6k 1.5×	1.9k 1.3×	1.5k 1.4×	1.4k 1.4×	357 0.6×	216	5.0k
Yasuhiro Koh Japan	32	2.0k 0.8×	801 0.5×	1.4k 1.3×	1.1k 1.1×	278 0.5×	131	3.3k
Dimitris Mavroudis Greece	43	3.9k 1.6×	2.4k 1.6×	1.5k 1.4×	1.6k 1.6×	352 0.6×	107	5.2k
George N. Naumov United States	22	2.3k 1.0×	1.1k 0.8×	1.3k 1.3×	1.9k 1.9×	267 0.5×	37	4.0k
Alison Backen United Kingdom	22	1.5k 0.7×	867 0.6×	573 0.6×	713 0.7×	275 0.5×	41	2.4k
Jaclyn Y. Hung United States	24	1.2k 0.5×	770 0.5×	1.3k 1.2×	1.4k 1.4×	491 0.9×	35	3.2k
Marija Balić Austria	30	2.5k 1.1×	1.6k 1.1×	737 0.7×	1.0k 1.0×	834 1.5×	123	3.8k
Wainer Zoli Italy	32	1.7k 0.7×	1.1k 0.7×	828 0.8×	1.4k 1.4×	233 0.4×	160	3.5k

Countries citing papers authored by Tim Ward

Since Specialization

Citations

This map shows the geographic impact of Tim Ward's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Ward with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Ward more than expected).

Fields of papers citing papers by Tim Ward

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Ward. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Ward. The network helps show where Tim Ward may publish in the future.

Co-authorship network of co-authors of Tim Ward

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Ward. A scholar is included among the top collaborators of Tim Ward based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Ward. Tim Ward is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ward, Tim, Duncan C. Gilbert, George Higginbotham, et al.. (2021). Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirations. The Journal of Pathology Clinical Research. 8(1). 3–13. 5 indexed citations

Dosa, Peter I., Tim Ward, Rui E. Castro, Cecília M. P. Rodrigues, & Clifford J. Steer. (2013). Synthesis and Evaluation of Water‐Soluble Prodrugs of Ursodeoxycholic Acid (UDCA), an Anti‐apoptotic Bile Acid. ChemMedChem. 8(6). 1002–1011. 23 indexed citations

Hou, Jianmei, Matthew Krebs, Tim Ward, et al.. (2011). Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer. American Journal Of Pathology. 178(3). 989–996. 343 indexed citations

Krebs, Matthew, Jianmei Hou, Robert Szczepaniak‐Sloane, et al.. (2011). Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. Journal of Thoracic Oncology. 7(2). 306–315. 371 indexed citations

Danson, Sarah, Peter Johnson, Tim Ward, et al.. (2011). Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. Annals of Oncology. 22(7). 1653–1660. 26 indexed citations

Greystoke, Alastair, James P.B. O’Connor, Kim Linton, et al.. (2011). Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. British Journal of Cancer. 104(4). 719–725. 38 indexed citations

Krebs, Matthew, Robert Szczepaniak‐Sloane, Lynsey Priest, et al.. (2011). Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(12). 1556–1563. 709 indexed citations breakdown →

Dive, Caroline, R A Smith, Elizabeth O. Garner, et al.. (2010). Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. British Journal of Cancer. 102(3). 577–582. 40 indexed citations

Hampson, Grace, Tim Ward, Jeff Cummings, et al.. (2010). Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. Journal of Immunological Methods. 360(1-2). 30–38. 25 indexed citations

10.

Backen, Alison, Jeffrey L. Cummings, Claire L. Mitchell, et al.. (2009). ‘Fit-for-purpose’ validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. Journal of Immunological Methods. 342(1-2). 106–114. 29 indexed citations

11.

Ranson, Malcolm, Emma Dean, Tim Ward, et al.. (2007). Cell death ELISAs in the phase I clinical evaluation of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7-days, 3-days, and 2-hours.. Molecular Cancer Therapeutics. 6.

12.

Booton, Richard, Tim Ward, Linda Ashcroft, et al.. (2007). ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 2(10). 902–906. 90 indexed citations

13.

Greystoke, Alastair, Andrew Hughes, Malcolm Ranson, et al.. (2007). Serum biomarkers of apoptosis. European Journal of Cancer Supplements. 5(5). 115–127. 3 indexed citations

14.

LaCasse, Eric C., Stephen Morris, Tim Ward, et al.. (2006). AEG35156, a XIAP antisense oligonucleotide, suppresses XIAP levels in targeted tissues isolated from pre-clinical models and from patients. Cancer Research. 66. 1142–1142. 3 indexed citations

15.

Booton, Richard, Tim Ward, Jim Heighway, et al.. (2006). Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum‐based chemotherapy in advanced nonsmall cell lung cancer. Cancer. 106(11). 2421–2427. 41 indexed citations

16.

Cummings, Jeff, Tim Ward, Malcolm Ranson, & Caroline Dive. (2004). Apoptosis pathway-targeted drugs—from the bench to the clinic. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1705(1). 53–66. 65 indexed citations

17.

Booton, Richard, et al.. (2003). P-43 Randomised phase III trial of docetaxel/carboplatin vs. MIC/MVP chemotherapy in inoperable Advanced non-small cell lung cancer (NSCLC) — Do XPD polymorphisms predict for sensitivity or resistance to platinum based chemotherapy. Lung Cancer. 41. S101–S102. 1 indexed citations

18.

Woolley, David E., et al.. (2002). Electrochemical Monitoring of Anticancer Compounds on the Human Ovarian Carcinoma Cell Line A2780 and Its Adriamycin- and Cisplatin-Resistant Variants. Experimental Cell Research. 273(1). 65–72. 27 indexed citations

19.

McGown, Andrew, Vikram S. Bajaj, Fiona Blackhall, et al.. (2000). p53 And related proteins in epithelial ovarian cancer. European Journal of Cancer. 36(18). 2317–2328. 37 indexed citations

20.

Ward, Tim, et al.. (1995). Cross-resistance studies on two K562 sublines resistant to diaziridinylbenzoquinones. Biochemical Pharmacology. 50(4). 459–464. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact